Amylyx (AMLX): Consensus Target
Amylyx Pharmaceuticals (AMLX) maintains a high reputation for developing therapies for rare brain pathologies, as confirmed by this trading chart featuring the 43.07 metric. Amylyx Pharmaceuticals (AMLX) implements advanced molecular neuron protection methods, blocking multiple mechanisms of cell decay. Supply stability is ensured by the proficient management of external orphan drug production through reliable contract partners.
Analytical breakdowns for Amylyx (AMLX)
- stock value and consensus price forecast:
- stock exchange capitalization data:
- book value of equity indicators:
- issuer credit burden and liquidity indicators:
Debt to Equity Ratio Amylyx Pharmaceuticals|AMLX - Long-Term Debt to Capital|Current Liabilities to Capital Amylyx Corp|AMLX - Company Total Debt|Debts to Book Capitalization Amylyx|AMLX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Amylyx Pharmaceuticals|Immediate Liquidity amylyx.com
- financial results and valuation multiples details:
AMLX - Net Profit|Projected Future Earnings Amylyx Pharmaceuticals|AMLX - Price to Earnings Ratio|Projected Price to Earnings Amylyx Pharmaceuticals Inc|AMLX - Price/Earnings to Growth Multiple|Company Value to EBITDA Amylyx|AMLX - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Amylyx Pharmaceuticals|AMLX - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months amylyx.com|AMLX - Net earnings per share growth this year|Projected earnings per share growth rate for next year Amylyx Pharmaceuticals
Summary company analytics:AMLX amylyx.com
Amylyx Pharmaceuticals (AMLX) occupies a strategic niche in the therapy of rare neurodegenerative pathologies. The innovativeness of its neuroprotective developments directly impacts business valuation models. This indicator represents the average target price established by analysts based on operational metrics. It measures the asset's fundamental potential while excluding market noise. By analyzing the trajectory of the consensus price forecast, an investor can determine the risk of overpaying for the asset.
Competitors of Amylyx Pharmaceuticals
Analyst Consensus Forecast biogen.com (BIIB)|Price Target Chart Neurocrine Biosciences, Inc. NBIX|RGC - Consensus Target|AXSM - Price Target Chart|ACAD: Price Target Chart|XENE (Xenon Pharmaceuticals) - Consensus Target|Broker Consensus Forecast VKTX|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast trevitherapeutics.com TRVI|PRAX - Price Target Chart|Fair Value Consensus AVXL (Anavex)|CeriBell Corp (CBLL) - Price Target Chart|Average Forecast Price Prothena Corporation plc (PRTA)|ALEC (Alector Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast annexonbio.com|Price Target Chart Omeros Corporation (OMER)|Consensus Target Neurogene Inc NGNE|AC Immune Corp - Consensus Target|Voyager Corp (VYGR) - Average Forecast Price|NMRA - Price Target Chart|SCLX: Price Target Chart|TVGN (Tevogen Bio) - Consensus Target|Average Forecast Price Alpha Cognition Inc. (ACOG)|Consensus Target CGTX|Broker Consensus Forecast IKT (Inhibikase Pharma)|Consensus Target SAVA (Cassava Sciences, Inc.)|ASRT (assertiotx.com) - Fair Value Consensus|Price Target Chart Coya Therapeutics COYA|VTGN (VistaGen Therapeutics, Inc.) - Forecast Levels Chart|Ovid Rx - Analyst Consensus Forecast|Fair Value Consensus ABOS (Acumen Pharmaceuticals, Inc)|CRVO: Analyst Consensus Forecast|Alterity Therapeutics Limited (ATHE) - Analyst Consensus Forecast|Price Target Chart Clene Inc|PEPG: Fair Value Consensus|Price Target Chart Jupiter Neurosciences Inc (JUNS)|Consensus Target Relmada Corp RLMD|Analyst Consensus Forecast ANVS (Annovis Bio, Inc.)|Analyst Consensus Forecast Grace Therapeutics Inc GRCE|Firefly Neuroscience - Analyst Consensus Forecast|Klotho Neurosciences Inc (KLTO) - Consensus Target|NRSN: Analyst Consensus Forecast|Average Forecast Price Reviva Pharmaceuticals, Inc. (RVPH)|Consensus Target MTVA|Analyst Consensus Forecast neuraxis.com|Consensus Target HSDT (Helius Medical)|Analyst Forecast Prices PASG|Analyst Consensus Forecast NEUP (Neuphoria Therapeutics)|Analyst Median Target Minerva (NERV)|Athira Pharma, Inc. - Analyst Consensus Forecast|addextherapeutics.com (ADXN) - Consensus Target|ALZN: Analyst Consensus Forecast|Cyclerion Therapeutics, Inc. (CYCN) - Analyst Consensus Forecast|Price Target Chart Protagenic Therapeutics Inc.|Price Target Chart KTTA|Price Target Chart Cortigent, Inc. (CRGT)|Analyst Median Target avenuetx.com|Analyst Consensus Forecast BCLI (BrainStorm Cell Therapeutics)|Analyst Consensus Forecast Cara Therapeutics Inc. CARA|CHRO - Price Target Chart|Eliem Therapeutics (ELYM) - Consensus Target|intracellulartherapies.com (ITCI) - Price Target Chart|LBPH (longboardpharma.com) - Price Target Chart|Consensus Target MRNS|Broker Consensus Forecast NKGN (NKGen Biotech Inc)|Price Target Chart NeuroBo (NRBO)|Sage Therapeutics Inc - Broker Consensus Forecast|Analyst Consensus Forecast SNPX (Synaptogenix, Inc.)|trevena.com (TRVN) - Average Forecast Price|VIGL: Consensus Target|WENA - Analyst Consensus Forecast|Cerevel (CERE) - Price Target Chart
